bioAffinity Technologies
BIAFW
4 hedge funds and large institutions have $65.2K invested in bioAffinity Technologies in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.23% more ownership
Funds ownership: 2.33% → 2.56% (+0.23%)
20% less funds holding
Funds holding: 5 → 4 (-1)
38% less capital invested
Capital invested by funds: $105K → $65.2K (-$40K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.91K |
| 2 |
OC
Oarsman Capital
Milwaukee,
Wisconsin
|
-$733 |
| 3 |
CS
Clear Street
New York
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $38.8K | – | – | – |
|
|
CS
2
Clear Street
New York
| $10.5K | -$5 | -11 | -0% |
|
|
3
UBS Group
Zurich,
Switzerland
| $9.17K | +$19.7K | +47,618 | +7,161% |
|
|
4
Citadel Advisors
Miami,
Florida
| $6.83K | -$5.91K | -14,257 | -28% |
|
|
OC
5
Oarsman Capital
Milwaukee,
Wisconsin
| – | -$733 | -2,448 | Closed |
|
BIAFW Hedge Fund Activity: Q1 2025 in Review
4 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q1 2025, worth a combined $65.2K — down 38% from $105K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BIAFW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $19.7K. The largest seller was Citadel Advisors, cutting an estimated $5.91K.
- 4 institutional investors held bioAffinity Technologies (BIAFW) as of Q1 2025, down from 5 in Q4 2024.
- Funds reported $65.2K of bioAffinity Technologies stock for Q1 2025, down 38% quarter-over-quarter.
- 0 funds opened new bioAffinity Technologies positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest bioAffinity Technologies buyer in Q1 2025 was UBS Group, an estimated $19.7K added.
- The largest bioAffinity Technologies seller in Q1 2025 was Citadel Advisors, an estimated $5.91K sold.
Based on aggregated 13F filings for Q1 2025.